2020
DOI: 10.1096/fasebj.2020.34.s1.09284
|View full text |Cite
|
Sign up to set email alerts
|

Transcriptomic landscape of lenalidomide‐treated NK cells: Functional enhancement by down‐regulation of CD161

Abstract: Lenalidomide is a potential immunomodulator that enhances the anti‐tumor effect of natural killer (NK) cells. However, the underlying molecular mechanism of anti‐tumor effects and long‐term activating effect on NK cells are unclear. Here, we report that lenalidomide in the long stimulation with interleukin‐2 (IL‐2) enhances the proliferation and specific anti‐tumor function of NK cells by modulating transcriptomic patterns, including downregulation of KLRB1 (CD161). In conclusion, the results suggest that lena… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles